

Resource Summary Report

Generated by [RRID](#) on Sep 4, 2026

769-P

RRID:CVCL_1050

Type: Cell Line

Proper Citation

KCB Cat# KCB 2013031YJ, RRID:CVCL_1050

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1050

Proper Citation: KCB Cat# KCB 2013031YJ, RRID:CVCL_1050

Description: Cell line 769-P is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Renal cell carcinoma

Defining Citation: [PMID:721102](#), [PMID:1010528](#), [PMID:6244232](#), [PMID:17178751](#), [PMID:20215515](#), [PMID:22185343](#), [PMID:22460905](#), [PMID:22949125](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:27993170](#), [PMID:28196595](#), [PMID:28489074](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 769-P

Synonyms: 769P, 769-p

Cross References: BTO:BTO_0006376, CLO:CLO_0001485, EFO:EFO_0002099, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1933, BioGRID_ORCS_Cell_line:501, BioSample:SAMN03473275, BioSample:SAMN10988198, cancercellines:CVCL_1050, CCRID:1101HUM-PUMC000333,

CCRID:3101HUMSCSP5060, CCRID:3101HUMTCHu215, CCRID:4201HUM-CCTCC00103, CCTCC:GDC0103, Cell_Model_Passport:SIDM00803, ChEMBL-Cells:ChEMBL3308705, ChEMBL-Targets:ChEMBL1075385, CLS:300106, Cosmic:687935, Cosmic:801355, Cosmic:910922, Cosmic:982280, Cosmic:1779197, Cosmic:2520640, Cosmic-CLP:910922, DepMap:ACH-000411, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:910922, GEO:GSM374479, GEO:GSM827256, GEO:GSM886844, GEO:GSM887908, GEO:GSM1669571, IARC_TP53:21154, IGRhCellID:769P, IZSLER:BS TCL 123, KCB:KCB 2013031YJ, LiGeA:CCLE_445, LINCS_LDP:LCL-1772, PharmacoDB:769P_27_2019, PRIDE:PXD030304, Progenetix:CVCL_1050, PubChem_Cell_line:CVCL_1050, Wikidata:Q54604830

ID: CVCL_1050

Vendor: KCB

Catalog Number: KCB 2013031YJ

Record Creation Time: 20220427T215059+0000

Record Last Update: 20260904T021122+0000

Ratings and Alerts

No rating or validation information has been found for 769-P.

No alerts have been found for 769-P.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 200 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Molotkova A, et al. (2026) ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis. Cancer research communications, 6(3), 477.

Wang J, et al. (2026) Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. Cancer research, 86(9), 2237.

Abou Alaiwi S, et al. (2026) Generation of a comprehensive epigenomic atlas in clear cell renal cell carcinoma informs kidney cancer progression and heritability. Cell reports, 45(2), 116968.

Hatayama T, et al. (2026) Nectin-4 drives aggressive tumor biology and poor prognosis in renal cell carcinoma. *Urologic oncology*, 44(8), 108.

Gu S, et al. (2026) MAGI3 deficiency unleashes β -catenin conformational change to drive metastatic progression and mTOR inhibitor resistance in ccRCC. *Cell death & disease*, 17(1).

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. *Cell death & disease*, 17(1).

Chen Y, et al. (2026) USP15 stabilizes c-Myc to drive sunitinib resistance by suppressing cuproptosis in clear cell renal cell carcinoma. *Cell reports*, 45(5), 117328.

Liao C, et al. (2026) Selective degradation of TBK1 uncovers mechanistic insights into blocking ccRCC progression. *Cell chemical biology*, 33(4), 461.

Yang T, et al. (2026) Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(42), e20237.

Lu Z, et al. (2025) Integrated single-cell and bulk transcriptome analysis revealed high plasticity subpopulation and promising diagnosis model for clear cell renal cell carcinoma. *Hereditas*, 162(1), 198.

Qu Y, et al. (2025) Proteogenomic Analysis Identifies Clinically Relevant Subgroups of Collecting Duct Carcinoma. *Research (Washington, D.C.)*, 8, 0859.

Zhang Q, et al. (2025) The extracellular-matrix-remodeling capability exposes therapeutic vulnerability in a subset of renal cell carcinomas with tumor thrombi. *Developmental cell*.

Luo J, et al. (2025) Machine learning-derived natural killer cell signature predicts prognosis and therapeutic response in clear cell renal cell carcinoma. *Translational oncology*, 51, 102180.

Jiang Q, et al. (2025) HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy. *Cell*, 188(7), 1807.

Johnson M, et al. (2025) Loss of SETD2 in wild-type VHL clear cell renal cell carcinoma sensitizes cells to STF-62247 and leads to DNA damage, cell cycle arrest, and cell death characteristic of pyroptosis. *Molecular oncology*, 19(4), 1244.

Zhu T, et al. (2025) Identification of IGF2BP3 and CENPA as key regulators of immunophenotypes in renal clear cell carcinoma. *Frontiers in genetics*, 16, 1749780.

Ye W, et al. (2025) TCIRG1 as a Novel Prognostic Biomarker Triggering Immune Infiltration in Renal Clear Cell Carcinoma: An Integrative Study of Single-Cell and Bulk Data. *Human mutation*, 2025, 1839494.

Shirole NH, et al. (2025) Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer. *Cancer discovery*, 15(7), 1484.

Takai Y, et al. (2025) Ankrd1 Promotes Lamellipodia Formation and Cell Motility via Interaction with Talin-1 in Clear Cell Renal Cell Carcinoma. *International journal of*

molecular sciences, 26(9).

Hase N, et al. (2025) APOBEC3C-mediated NF- κ B activation enhances clear cell renal cell carcinoma progression. *Molecular oncology*, 19(1), 114.